Retina Synthesis

We discuss a novel mechanism of action for the treatment of diabetic macular edema and neovascular AMD with Phase I/II trial results Dr. Raj Maturi, Midwest Eye Institute, Indiana University School of Medicine.

We review lesion progression in the eighteen month data with Roger Goldberg, MD, MBA of Bay Area Retina Associates, Walnut Creek, California.

We discuss the role that clinicians can play in fostering innovation in the retinal pharmacotherapy space with Dr. Eliot Lazar.

We discuss the 12 month results of the Phase I Davio Trial of an innovative TKI agent for the sustained treatment of neovascular AMD with Dr. Rishi Singh, Professor of Ophthalmology, Cole Eye Insitute, President, Cleveland Cllinic-Martin Hospital, Stuart, Florida.

We discuss treat and extend versus alternate dosing strategies to treat center involving diabetic macular edema with Dr. Varun Chaudhary, Chief of Ophthalmology, Hamilton Regional Eye Center and Professor, McMaster University.

We discuss the role of IOP pressure elevation following intravitreal anti-VEGF therapy with Parnian Arjmand, MD, MSC, FCSRS of the Toronto Retina Institute.

We discuss real world experience about faricimab with Dr. Carl Danzig of Pompano Beach, Florida.

We discuss new treatment options and clinical trials for radiation retinopathy with Prithvi Mruthyunjaya MD Professor of Ophthalmology, Stanford Medical School, Director of Ocular Oncology, Byers Eye Institute.

We discuss new developments in gene therapy for inherited retinal diseases with Sue Washer, President and CEO of AGTC.

We discuss a novel strategy using RNA anti sense technology for treating geographic atrophy with Dr. Nik London,  San Diego, California.

We discuss the 18 month results of the Derby and Oaks trials of pegcetacoplan for treatment of geographic atrophy with Roger Goldberg, MD of Walnut Creek, California.

We discuss a new retinal sealant that may replace the need for tamponade with expansile gas or silicone oil with Dr. James Anthony Stefater.

We discuss how new developments in imaging and therapeutics have impacted the treatment of sickle cell retinopathy with Dr. Adrienne Scott, Professor of Ophthalmology at Johns Hopkins and the Wilmer Eye Institute.

We discuss the results of a Phase II clinical trail studying the efficacy of high dose aflibercept (8mg) for treating neovascular AMD with Dr. David Brown of Retina Consultants of Texas in Houston.

We discuss new developments in the diagnosis and therapy of choroidal melanoma with Dr. Paul Finger, Clinical Professor, NYU and Chair, Eye Cancer Foundation.

We discuss the two year results of a Phase I/II trial of a stem cell  implant for the treatment of geographic atrophy with Dr. Amir Kashani, Associate Professor, Wilmer Eye Institute.

We discuss the one year results of the DERBY and OAKs studies treating geographic atrophy with Dr. David Lally,  Assistant Professor University of Massachusetts and Tufts University.

We discuss the use of deep learning techniques in the detection and management of macular degeneration with Dr. Pearse Keane, Consultant Moorfields Eye Hospital, Professor of Artificial Medical Intelligence University College London.

In our latest update, We discuss the use of APX3330 a novel oral agent for the treatment of diabetic retinopathy with Dr. David Boyer, Retina Vitreous Associates, Adjunct Professor USC Roski Eye Institute.

We discuss the use of a home based OCT system with artificial intelligence to monitor the treatment of neovascular AMD with Dr. Nancy Holekamp, Professor of Clinical Ophthalmology, Washington University School of Medicine.

We discuss the two year results of the first bispecific agent for the treatment of diabetic macular edema with Dr. John Wells III, from Palmetto Retina Clinic.

We discuss the results of the Kingfisher trail, a study employing broluizumab q4 weeks for the treatment of diabetic macular edema with Dr. Mark Barakat, Assistant Clinical Profess of Ophthalmology, University of Arizona College of Medicine Phoenix.

We examine the role of sub retinal fluid in the treatment of neovascular AMD with Dr. David Sarraf, Professor of Ophthalmology, UCLA Stein Eye Institute.

We discussed and learned with Samarendra Mohanty, PhD: President and Founder of Nanoscope Technologies, about the fascinating science of vision restoration through making bipolar cells light-sensitive and the development program of the intravitreally administered gene therapy vMCO-010c, currently being investigated in a Ph2b trial of patients with retinitis pigmentosa.

We discuss a phase I study examining the effect of plasma kvllikrein inhibition on diabetic macular edema with Dr. Arshad Khanani, Sierra Eye Associates, University of Nevada Reno.